Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Gemcitabine + Carboplatin in TNBC
NCT01201265Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple negative breast cancer (TNBC), sponsored by Roche. Started Feb 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01201265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01201265.